ArticleJournal of molecular modeling2026
Phytochemical modulation of DNMT1-mediated DNA methylation: computational insights into breast cancer.
Article in Journal of molecular modeling, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
contextAberrant DNA methylation, particularly DNMT1-mediated hypermethylation of tumor suppressor and DNA repair genes, contributes to breast cancer progression. The limitations associated with existing DNMT inhibitors highlight the need for alternative and potentially safer epigenetic modulators. Here, we developed a computational workflow to identify phytochemicals targeting the catalytic methyltransferase domain of DNMT1. Screening of the SelleckChem phytochemical library identified Echinacoside (-9.56 kcal/mol), 1,2,3,4,6-O-Pentagalloylglucose (-9.49 kcal/mol), and Complanatoside A (-9.24 kcal/mol) as promising candidates based on favourable docking and interaction profiles. Among them, 1,2,3,4,6-O-Pentagalloylglucose exhibited most favorable predicted binding free energy (- 105.31 ± 5.51 kcal/mol) and maintained stable interactions throughout 500 ns molecular dynamics simulation. DFT, PCA, FEL, and QM/MM analyses further supported its favorable electronic characteristics and conformational stability within the DNMT1 catalytic pocket.
methodsStructure-based virtual screening, molecular docking, DFT, 500 ns molecular dynamics simulations, MM/GBSA, PCA, FEL, and QM/MM analyses were integrated to characterize ligand binding, stability, and electronic interactions. These findings represent purely in silico predictions and require experimental validation to establish the DNMT1 inhibitory potential of the identified compounds and their therapeutic relevance.
Indexed as
Identifiers
42891767What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.